The dolutegravir/valproic acid drug–drug interaction is primarily based on protein displacement

Abstract Objectives The dolutegravir/valproic acid drug–drug interaction (DDI) is suggested to be caused by protein displacement. Here, we assess the underlying mechanism. Methods Participants in a randomized controlled trial investigating valproic acid as an HIV latency reversing agent were recruit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2021-04, Vol.76 (5), p.1273-1276
Main Authors: Bollen, P D J, Prins, H A B, Colbers, A, Velthoven-Graafland, K, Rijnders, B J A, de Vries-Sluijs, T E M S, van Nood, E, Nouwen, J, Bax, H, de Mendonca Melo, M, Verbon, A, Burger, D M, Rokx, C
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives The dolutegravir/valproic acid drug–drug interaction (DDI) is suggested to be caused by protein displacement. Here, we assess the underlying mechanism. Methods Participants in a randomized controlled trial investigating valproic acid as an HIV latency reversing agent were recruited in a predefined pharmacokinetic substudy if they were on once-daily 50 mg dolutegravir-containing combination ART (cART) for >12 months with a plasma HIV-RNA
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkab021